证券代码：002675 证券简称：东诚药业 公告编号：2026-012 烟台东诚药业集团股份有限公司 关于 225Ac-LNC1011 注射液 I 期临床试验 完成首例参与者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）控股子公司烟 台蓝纳成生物技术股份有限公司（以下简称"蓝纳成"）自主研发的 225Ac-LNC1011 注射液 I/II 期临床完成了首例参与者入组。该研究为一项评价 225Ac-LNC1011 注 射液在前列腺特异性膜抗原（PSMA）阳性的转移性去势抵抗性前列腺癌（mCRPC） 患者中的安全性、耐受性、药代动力学及初步有效性的 I/II 期临床试验。 药品从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容 易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。 公司将按相关国家的有关规定积极推进上述研发项目，并及时对项目后续进展情 况履行信息披露义务。 特此公告。 烟台东诚药业集团股份有限公司董事会 二、药物的其他情况 1、225Ac-LNC10 ...

证券代码：002675 证券简称：东诚药业 公告编号：2026-011 烟台东诚药业集团股份有限公司 关于回购公司股份进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"）于2025年12月31日召开 第六届董事会第十七次会议，审议通过了《关于以集中竞价方式回购股份方案的 议案》，同意公司使用自有资金及自筹资金以集中竞价交易的方式回购公司股份， 回购的股份将用于实施股权激励和/或员工持股计划。回购价格不超过人民币 18.00元/股（含），回购资金总额不低于人民币10,000万元（含），不超过人民 币20,000万元（含），回购期限自公司董事会审议通过回购股份方案之日起不超 过12个月。具体内容详见公司于2026年1月5日、2026年1月6日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于以集中竞价方式回购股份方案的公告》、 《回购报告书》。 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 规定，回购期间公司应当在每个月的前三个交易日内披露截至上月末的回购进展 情况。现 ...

Group 1 - Dongcheng Pharmaceutical's stock increased by 0.97% on February 25, with a trading volume of 112 million yuan. The financing buy amount was 14.88 million yuan, while the financing repayment was 9.10 million yuan, resulting in a net financing buy of 5.78 million yuan. The total financing and securities balance reached 1.075 billion yuan as of February 25 [1] - The financing balance of Dongcheng Pharmaceutical is 1.075 billion yuan, accounting for 9.65% of the circulating market value, which is above the 70th percentile level over the past year, indicating a relatively high position [1] - On the same day, there were no shares repaid or sold in the securities lending market, with a remaining amount of 12,900 shares and a securities lending balance of 174,100 yuan, which is below the 10th percentile level over the past year, indicating a low position [1] Group 2 - As of September 30, the number of shareholders of Dongcheng Pharmaceutical was 24,600, an increase of 4.51% compared to the previous period. The average circulating shares per person decreased by 4.32% to 30,191 shares [2] - For the period from January to September 2025, Dongcheng Pharmaceutical reported operating revenue of 2.043 billion yuan, a year-on-year decrease of 5.52%. The net profit attributable to the parent company was 149 million yuan, down 10.64% year-on-year [2] - Since its A-share listing, Dongcheng Pharmaceutical has distributed a total of 1 billion yuan in dividends, with 293 million yuan distributed over the past three years. As of December 31, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 20.2793 million shares, an increase of 252,100 shares compared to the previous period [3]

证券代码：002675 证券简称：东诚药业 公告编号：2026-010 烟台东诚药业集团股份有限公司 关于为下属公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次担保情况概述 近日，烟台东诚药业集团股份有限公司（以下简称"公司"）与中国光大银 行股份有限公司烟台分行（以下简称"光大银行"或"债权人"）签订了《保证 合同》，约定公司为下属公司烟台东诚核源技术开发有限公司（以下简称"东诚 核源"或"债务人"）向光大银行申请的20,000万元贷款提供连带责任担保。 二、担保事项审议及额度使用情况 公司于2025年2月26日和2025年3月28日分别召开第六届董事会第九次会议 和2024年度股东大会，审议通过了《关于2025年度为子公司及其下属公司提供担 保额度预计的议案》，同意公司对合并报表范围内的子公司及其下属公司提供担 保，预计2025年度上述担保额度合计不超过人民币100,000万元（或等值外币）， 额度内可循环滚动操作。授权公司及子公司法定代表人或其授权人员根据实际经 营需要，在前述额度内分别代表其所在公司签署相关文件。 内容详 ...

Core Viewpoint - Dongcheng Pharmaceutical (002675) announced a share buyback plan, indicating a commitment to enhancing shareholder value through the repurchase of its own shares [1] Group 1: Share Buyback Details - As of January 31, 2026, the company has repurchased a total of 4,028,699 shares [1] - The repurchased shares represent 0.49% of the company's total share capital [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, with a focus on companies like Haoyuan Pharmaceutical and Aopumai [1]. Core Insights - The report highlights a recovery in the upstream research sector supported by interest rate cuts and other factors, indicating a renewed focus on early-stage research projects by pharmaceutical companies [4][16]. - The A-share pharmaceutical index has shown a year-to-date increase of 3.14%, outperforming the CSI 300 index by 2.51% [4]. - The report emphasizes the importance of innovation in drug development, particularly in early-stage projects, and suggests that the demand for life sciences services will increase as funding becomes more available [4][16]. Summary by Sections Industry Trends - The A-share pharmaceutical index has decreased by 3.31% this week, while the Hang Seng Biotechnology Index has decreased by 3.24% [4][9]. - The report notes that the pharmaceutical sector is experiencing a rebound in demand, driven by both domestic and international factors, including a resurgence in IPOs and funding opportunities [16][18]. Research and Development Progress - The report details significant advancements in innovative drugs and improved drugs, with several companies submitting applications for new drug approvals [20]. - Companies like Roche and Relay Therapeutics are making strides in clinical trials, with Roche submitting an application for Giredestrant for breast cancer treatment [4][20]. Recommended Stocks - The report suggests focusing on specific companies based on sub-industry strengths, including: - CXO and upstream research services: WuXi AppTec, Haoyuan Pharmaceutical, Aopumai, and King’s Ray Biotechnology [12]. - Traditional Chinese medicine: Jichuan Pharmaceutical, Zuoli Pharmaceutical, and Fangsheng Pharmaceutical [12]. - PD1 PLUS: 3SBio, Kangfang Biotech, and Innovent Biologics [12]. - ADC: InnoCare Pharma and Kelun-Biotech [12]. - AI drug development: Jingtaikong Holdings [12].

Group 1 - Dongcheng Pharmaceutical announced a share buyback plan, repurchasing approximately 4.03 million shares, which accounts for 0.49% of the total share capital [1] - The buyback was conducted through a centralized bidding method, with a total expenditure of approximately RMB 57.17 million [1] - The highest transaction price during the buyback was RMB 14.74 per share, while the lowest was RMB 13.87 per share [1] Group 2 - The news highlights a significant market reaction to external events, particularly related to Trump, which caused gold prices to drop sharply [1] - Over the previous two weeks, gold prices had surged by 21%, indicating high volatility in the market [1] - Various institutions have provided their outlooks on the future market trends following these events [1]

Core Viewpoint - Dongcheng Pharmaceutical announced a share buyback plan, repurchasing 4,028,699 shares, which represents 0.49% of the total share capital, with a total expenditure of approximately RMB 57.17 million [1] Group 1 - The company conducted the share buyback through a dedicated securities account via centralized bidding [1] - The highest transaction price during the buyback was RMB 14.74 per share, while the lowest was RMB 13.87 per share [1] - The buyback aligns with relevant laws and regulations as well as the company's established share repurchase plan [1]

证券代码：002675 证券简称：东诚药业 公告编号：2026-009 烟台东诚药业集团股份有限公司 关于回购公司股份进展情况的公告 二、其他说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托 时段符合《深圳证券交易所上市公司自律监管指引第9号——回购股份》的相关 规定。具体说明如下： 1、公司未在下列期间内回购股票： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"）于2025年12月31日召开 第六届董事会第十七次会议，审议通过了《关于以集中竞价方式回购股份方案的 议案》，同意公司使用自有资金及自筹资金以集中竞价交易的方式回购公司股份， 回购的股份将用于实施股权激励和/或员工持股计划。回购价格不超过人民币 18.00元/股（含），回购资金总额不低于人民币10,000万元（含），不超过人民 币20,000万元（含），回购期限自公司 ...

Group 1 - The core viewpoint of the news highlights significant projected profit increases for various companies in 2025, driven by rising production and sales in precious metals and advancements in technology sectors [1][3]. Group 2 - Xiaocheng Technology anticipates a net profit increase of 93%-179% year-on-year in 2025, with growth in gold production, sales, and international gold prices [1]. - Hunan Silver expects a net profit increase of 67.88%-126.78% in 2025, supported by rising silver and gold production and sales [3]. - Industrial Fulian projects a 56%-63% year-on-year increase in net profit for Q4 2025, with AI server revenue growth exceeding 50% quarter-on-quarter and over 5.5 times year-on-year [3]. - Keda Xunfei forecasts a net profit increase of 40%-70% in 2025, benefiting from the scaling of artificial intelligence applications [3]. - Albitex anticipates a net profit increase of 100.96% in 2025, primarily due to its focus on aerospace and expansion into the civilian market [3]. - Companies like Hainan Mining and Meixin Sheng are also making strategic acquisitions and investments to enhance their market positions [3].